Kendall J Keck1, Jessica E Maxwell1, Yusuf Menda2, Andrew Bellizzi3, Joseph Dillon4, Thomas M O'Dorisio4, James R Howe5. 1. Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, IA. 2. Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, IA. 3. Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA. 4. Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA. 5. Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, IA. Electronic address: james-howe@uiowa.edu.
Abstract
BACKGROUND: Patients with gastroenteropancreatic neuroendocrine tumors often present with metastases. Identification of the primary tumor is important for operative management, and therefore we sought to determine our success at identifying primary tumors with diagnostic testing and operative exploration. METHODS: A clinical neuroendocrine tumor database was reviewed to identify patients presenting with metastases and primary tumor in situ. Results of radiologic, endoscopic, and operative procedures were evaluated to determine which correctly identified the primary tumor. RESULTS: There were 197 patients presenting with metastases and unresected primaries, 134 who had an operation and 63 managed nonoperatively. Primaries were identified preoperatively in 168 (84%), at operative exploration in 7, and were not found in 22 patients. Computed tomography found 150/197 primary tumors, somatostatin-receptor scintigraphy 88/155, and endoscopy 43/107. The sensitivity of computed tomography surpassed scintigraphy (76% vs 57%, P < .01). The primary was removed in 130/134 (97%) patients, and hepatic debulking was performed in 67%. Median survival for operative patients with small bowel and pancreatic tumors was 145 and 71 months, respectively. CONCLUSION: Imaging and endoscopy identified the primary tumor in most patients, and the majority of the others were found at exploration. Preoperative testing facilitated operative planning, allowing for resection of the primary and hepatic debulking in most patients.
BACKGROUND:Patients with gastroenteropancreatic neuroendocrine tumors often present with metastases. Identification of the primary tumor is important for operative management, and therefore we sought to determine our success at identifying primary tumors with diagnostic testing and operative exploration. METHODS: A clinical neuroendocrine tumor database was reviewed to identify patients presenting with metastases and primary tumor in situ. Results of radiologic, endoscopic, and operative procedures were evaluated to determine which correctly identified the primary tumor. RESULTS: There were 197 patients presenting with metastases and unresected primaries, 134 who had an operation and 63 managed nonoperatively. Primaries were identified preoperatively in 168 (84%), at operative exploration in 7, and were not found in 22 patients. Computed tomography found 150/197 primary tumors, somatostatin-receptor scintigraphy 88/155, and endoscopy 43/107. The sensitivity of computed tomography surpassed scintigraphy (76% vs 57%, P < .01). The primary was removed in 130/134 (97%) patients, and hepatic debulking was performed in 67%. Median survival for operative patients with small bowel and pancreatic tumors was 145 and 71 months, respectively. CONCLUSION: Imaging and endoscopy identified the primary tumor in most patients, and the majority of the others were found at exploration. Preoperative testing facilitated operative planning, allowing for resection of the primary and hepatic debulking in most patients.
Authors: Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki Journal: Ann Surg Date: 2007-02 Impact factor: 12.969
Authors: Skye C Mayo; Mechteld C de Jong; Carlo Pulitano; Brian M Clary; Srinevas K Reddy; T Clark Gamblin; Scott A Celinksi; David A Kooby; Charles A Staley; Jayme B Stokes; Carrie K Chu; Alessandro Ferrero; Richard D Schulick; Michael A Choti; Giles Mentha; Jennifer Strub; Todd W Bauer; Reid B Adams; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2010-06-29 Impact factor: 5.344
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi Journal: Eur J Nucl Med Date: 1993-08
Authors: Fadi S Dahdaleh; Allison Lorenzen; Maheen Rajput; Jennifer C Carr; Junlin Liao; Yusuf Menda; Thomas M O'Dorisio; James R Howe Journal: Ann Surg Oncol Date: 2013-01-03 Impact factor: 5.344
Authors: Joshua S Hill; James T McPhee; Theodore P McDade; Zheng Zhou; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng Journal: Cancer Date: 2009-02-15 Impact factor: 6.860
Authors: Jessica E Maxwell; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe Journal: Surgery Date: 2015-10-09 Impact factor: 3.982
Authors: Edmund K Bartlett; Robert E Roses; Meera Gupta; Parth K Shah; Kinjal K Shah; Salman Zaheer; Heather Wachtel; Rachel R Kelz; Giorgos C Karakousis; Douglas L Fraker Journal: J Surg Res Date: 2013-04-25 Impact factor: 2.192
Authors: James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier Journal: Pancreas Date: 2017-07 Impact factor: 3.327
Authors: Allen B Choi; Jessica E Maxwell; Kendall J Keck; Andrew J Bellizzi; Joseph S Dillon; Thomas M OʼDorisio; James R Howe Journal: Pancreas Date: 2017-10 Impact factor: 3.327